that induced by antidepressants has not been documented. The antidepressant-induced manic psychosis was associated with worsening of existing tics, which is similar to previous reports (Berthier et al., 1998) . Though clomipramine has been associated with exacerbation of tics (Kumar &Lang, 1997), emergence of new-onset coprolalia due to antidepressants has only been anecdotally cited (Delgado etal., 1990) . Such an observation encourages further exploration of the role of antidepressant-induced cycling as a course modifier in TS.
Another point that needs to be addressed is whether there is a subgroup of TS patients who are prone for bipolarity. A study showed that the risk of bipolar disorder in a group of patients with TS is at least four times greater than would be expected by chance (Kerbeshian et al., 1995) . I The defining characteristics of this sub-group of patients include male adolescents who have mild tics and comorbid psychiatric diagnoses (Berthier et al., 1998) . Our patient had all these characteristics and thus it could be argued that his propensity for bipolarity was unmasked by the antidepressant. Hence, through this report authors emphasize exercising caution while prescribing antidepressants to such patients of TS as defined above. This is pertinent to cases of TS with comorbid OCD wherein antidepressants are prescribed to treat the latter condition. Use of antidepressants with a lesser potential for causing a manic switch such as selective serotonin reuptake inhibitors or concurrent use of mood stabilizers can be explored in a similar situation. 
REFERENCES

RESEARCH IN INDIA: NOT GOOD ENOUGH?
Sir, At the recent Mid-Term National CME of the Indian Psychiatric Society in Nagpur, two lectures caught my attention. One lecture aimed to provide a review of the research on schizophrenia from India. The review was very comprehensive and systematic. The speaker concluded that, despite the large volume of work, the majority of research was poor in design, had limited value as evidence for practice, and lacked originality. The second lecture, by the editor of this journal, was on the evidence base for the treatment for schizophrenia It was notable, as a member of the audience remarked, that not a single Indian study was cited in the evidence base. Not surprisingly, we were informed that no Indian study made the required mark to be considered as good enough evidence for the treatment of schizophrenia. Not a SINGLE Indian study! This is remarkable given that India has one of the largest number of psychiatrists in teaching or academic positions in any developing country. The usual reason we hear for the lack of quality research from India focuses on two themes: not enough money, and not enough manpower. While there is some truth in both these allegations, I would suggest that the most important reason of all is the lack of research skills and opportunity in academic institutions.
In fact, over the past few years, I have become aware of the enormous potential for original, innovative and significant research in psychiatry in India. The first, and most important, resource is the large number of trainee psychiatrists who must complete a research dissertation for their MD or DNB degrees. India is one of the few countries where a clinical psychiatric qualification requires a compulsory research dissertation. How many of the hundreds of such dissertations, however, actually involve innovative research? How many of these end up as research papers? The second major resource is the considerable amounts of funds being invested by pharmaceutical companies for drug trials for licencing and marketing purposes in India. Our society journal is filled with treatment trials, but yet few (if any) meet the standards required to be cited as evidence for practice. The reasons are simple to anyone who is familiar with the Consort Guidelines for trials (Moher, Schulz, & Alman 2001) ; virtually none of the trials meet the essential criteria of being randomized, controlled, with some efforts for masking and with an adequate sample size. The result: dozens of trials with very little evidence being generated.
The current global attention to mental health in developing countries has also led to considerable interest in funding mental health research in India from international donor agencies. Examples of such agencies include the Wellcome Trust, the MacArthur Foundation and the PPP Foundation. Yet, many of these donors complain that either there are very few research proposals coming their way, or they are woefully substandard in their conception and design. Even when pharmaceutical companies fund research, many researchers simply adopt the company protocol; rarely is there an effort to ensure that the research is scientifically important. Another major limitation of much of the research from India is that it is not population based. In fact, the majority of research articles arise from psychiatric or tertiary hospital settings, in contrast to the fact that overwhelming majority of mental illness in our country is not seen in these settings. Thus, the context of the research is out of step with the epidemiological reality. Even though we constantly hear that treatment evidence needs to be generated from our setting (Patel, 2000) , there is pitiful little quality research demonstrating this. The results are predictable: top psychiatric journals carry hardly any articles from developing countries and only a tiny fraction of these describe interventions (Patel & Sumathipaia, 2001) .
It is time that we take stock of the reality that Indian psychiatry is still unable to produce a significant impact on psychiatry as a medical and public health discipline both in our country and globally. I would argue that the single most important reason for this is the lack, not of manpower or funds, but of skills in research methodology. Even today, there are no formal training programs in research methodology in the vast majority of post-graduate training schemes. Teachers are appointed solely on the basis of their academic seniority, rather than academic ability. Thus, persons with little research training or ability themselves become the supervisors of MD dissertations of the new generation of psychiatrists. This problem exists overseas too, but schemes for research methodology are now becoming widespread as a means to strengthen the academic skills of trainees. The way forwards is clear: regular training schemes are essential, particularly in epidemiology which lies at the heart of medical research. The Indian Psychiatric Society could play a central role in this regard. It is impossible to expect each medical school to establish its own training scheme, particularly since many departments have only a handful of trainees. The IPS could provide the basis of holding regular epidemiology training workshops, perhaps one in each zone, on an annual basis. Already, some pharmaceutical companies are organising "updates" for trainees in each zone. These workshops could be conducted by the many skilled researchers in the country, and would aim not only to teach research methods but also to strengthen inter-department research collaborative networks, teach how to write research proposals and to access funds from the growing number of donor agencies. Let us be hopeful that psychiatric research in India can capitalise on the considerable strengths it already has. The solution appear relatively straightforward. Does our Society have the will? Rohtak-124001 Haryana(lndia) ('122/8, Shivaji Colony, Rohtak-124001 
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NOTES & NEWS NEW RESEARCH FUNDS AVAILABLE FOR TREATMENT TRIALS FOR SCHIZOPHRENIA AND BIPOLAR DISORDER
The Stanley Foundation announces the availability of $10-$15 million per year in new funds specifically designated to support clinical trials for schizophrenia or bipolar disorder The Foundation will support studies on compounds in development, studies on the off-label use of existing compounds, and studies of novel and indigenous compounds that may be of benifit for these disorders. A variety of study designs will be considered, including adjunctive trials, uncontrolled pilot trials, and randomized controlled trials. Trials may be from single site or from multiple collaborating sites. A complete list of drug trials currently being supported by the Foundation is available at www Stanley research org.
Funding for the trials may range from $50,000 up to $ 300,000 per year for up to three years depending on the design Indirect costs can be paid up to 15 percent as part of the total grant Submissions will be reviewed by a scientific advisory board Application can be submitted online at www.stanleyresearch.org. 
